Antibody for gastric cancer progresses to Phase III trials

Gastric cancer

The US Food and Drug Administration (FDA) has granted clearance to Transcenta to proceed with its TranStar 301 global Phase III pivotal trial of Osemitamab (TST001) for gastric cancer.

The trial will investigate the drug in combination with Nivolumab and chemotherapy as a first-line treatment in patients with HER2-negative, CLDN18.2 expressing locally advanced or metastatic gastric or gastroesophageal (G/GEJ) adenocarcinoma.

The company received approvals from the Center for Drug Evaluation (CDE) in China and MFDS in South Korea for the Phase III pivotal trial of Osemitamab in July 2023.

Though treatment outcomes for stomach cancer have improved, the median overall survival of nivolumab plus chemotherapy, the current standard of care, is still less than 14 months.

Osemitamab is a second-generation humanised CLDN18.2 targeting antibody with improved CLDN18.2 binding affinity and enhanced antibody-dependent cellular cytotoxicity (ADCC). It has shown anti-tumour activities in preclinical tumour models with a broad range of CLDN18.2 expression.

“We are delighted with the positive outcome of the EOP2 meeting,” said Dr Caroline Germa, Transcenta Executive Vice President, Global Medicine Development and Chief Medical Officer. “The interim safety, clinical pharmacology and efficacy data we presented fostered a productive dialogue with the FDA. Securing FDA endorsement on critical programme elements represents a pivotal milestone in advancing our Phase III trial in the US.”

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free